Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

IVUS-Guided Coronary Angioplasty: Promising Results at 3-Year Follow-Up

Intravascular ultrasound (IVUS) to guide drug-eluting stent (DES) implantation has been evaluated in several studies. Two randomized studies, IVUS-XPL (Impact of Intravascular Ultrasound Guidance on the Outcomes of Xience Prime Stents in Long Lesions) and ULTIMATE (Intravascular Ultrasound Guided Drug Eluting Stents Implantation in All-Comers Coronary Lesions), have shown fewer repeat revascularizations compared with angiography-guided stent implantation. However, there were no differences in terms of cardiovascular death, stent thrombosis, or AMI; this was linked to the low number of events in each study.

Angioplastia coronaria guiada con IVUS: resultados alentadores en el seguimiento a 3 años

The aim of this study was to analyze patients from the IVUS-XPL and ULTIMATE studies to increase the statistical power that would allow researchers to detect whether IVUS-guided DES implantation has a long-term impact on patient survival (free from cardiovascular death). To do so, only lesions with a length ≥28mm were evaluated.

The primary endpoint (PEP) was cardiovascular death. The secondary endpoint (SEP) was a composite of cardiovascular death, AMI, stent thrombosis, and ischemia-driven revascularization.

The study enrolled 2577 randomized patients, 1289 to the IVUS-guided group, and 1288 to the angiography-guided group.

The mean age was 65 years, 70% of patients were male, and over half of them had hypertension. The most frequent clinical presentation was unstable angina. The most affected artery was the anterior descending artery.

Read also: Passive Leg Raise: An Indispensable Maneuver in the Study of Heart Failure with Preserved Ejection Fraction.

The PEP was reached in 1% of the IVUS group vs. 2.2% of patients in the angiography group (hazard ratio [HR]: 0.43; 95% confidence interval [CI]: 0.22 to 0.84; p = 0.011). Furthermore, there were significant differences in favor of the IVUS group in the SEP (HR: 0.44; 95% CI: 0.25 to 0.80; p = 0.005) at the expense of a lower ischemia-driven revascularization rate (HR: 0.57; 95% CI: 0.40 to 0.82; p = 0.002).

At the 3-year follow-up, patients who met IVUS-measured stent optimization criteria had experienced fewer events (composite of cardiovascular death, AMI, stent thrombosis, and ischemia-driven revascularization) compared with those who did not meet optimization criteria.

Conclusion

Using IVUS to guide DES implantation compared with angiography alone resulted in improved cardiovascular survival and a decreased rate of major events (cardiovascular death, AMI, stent thrombosis) at the 3-year follow-up. In addition, patients who met the criteria for stent optimization compared with those who did not had significantly lower rates of cardiovascular death, AMI, stent thrombosis, and revascularization of the treated vessel at follow-up.

Dr. Andrés Rodríguez
Member of the editorial board in SOLACI.org .

Original Title: Improved 3-Year Cardiac Survival After IVUS–guided Long DES Implantation A Patient-Level Analysis From 2 Randomized Trials.

Reference: Sung-Jin Hong, MD, et al J Am Coll Cardiol Intv 2022;15:208–216.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...